$0.5
+0.05
(+11.36%)▲
12.08%
Downside
Day's Volatility :12.78%
Upside
0.79%
16.6%
Downside
52 Weeks Volatility :89.36%
Upside
87.24%
Period | Sol-gel Technologies Ltd | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -49.43% | 6.5% | 0.0% |
6 Months | -62.51% | 7.1% | 0.0% |
1 Year | -87.47% | 9.8% | 0.0% |
3 Years | -96.28% | 14.2% | -20.2% |
Market Capitalization | 18.7M |
Book Value | $1.17 |
Earnings Per Share (EPS) | -0.81 |
Wall Street Target Price | 6.0 |
Profit Margin | 0.0% |
Operating Margin TTM | -1440.34% |
Return On Assets TTM | -35.07% |
Return On Equity TTM | -59.6% |
Revenue TTM | 1.7M |
Revenue Per Share TTM | 0.06 |
Quarterly Revenue Growth YOY | -38.5% |
Gross Profit TTM | -8.8M |
EBITDA | -24.7M |
Diluted Eps TTM | -0.81 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.83 |
EPS Estimate Next Year | -0.5 |
EPS Estimate Current Quarter | -0.15 |
EPS Estimate Next Quarter | -0.18 |
What analysts predicted
Upside of 1100.0%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 129.0K | ↓ 25.86% |
Net Income | -32.2M | ↑ 2.01% |
Net Profit Margin | -25.0K% | ↓ 6821.04% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 22.9M | ↑ 17655.04% |
Net Income | -24.6M | ↓ 23.58% |
Net Profit Margin | -107.44% | ↑ 24856.13% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 8.8M | ↓ 61.71% |
Net Income | -27.4M | ↑ 11.35% |
Net Profit Margin | -312.4% | ↓ 204.96% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 31.3M | ↑ 256.54% |
Net Income | 4.4M | ↓ 115.9% |
Net Profit Margin | 13.94% | ↑ 326.34% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 3.9M | ↓ 87.58% |
Net Income | -13.6M | ↓ 412.12% |
Net Profit Margin | -350.3% | ↓ 364.24% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 1.6M | ↓ 59.98% |
Net Income | -27.2M | ↑ 100.25% |
Net Profit Margin | -1.8K% | ↓ 1402.47% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 100.0K | ↓ 61.69% |
Net Income | -4.9M | ↑ 66.44% |
Net Profit Margin | -4.9K% | ↓ 3806.69% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 758.0K | ↑ 658.0% |
Net Income | -31.1M | ↑ 529.54% |
Net Profit Margin | -4.1K% | ↑ 838.01% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 594.0K | ↓ 21.64% |
Net Income | -6.0M | ↓ 80.82% |
Net Profit Margin | -1.0K% | ↑ 3101.94% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 213.0K | ↓ 64.14% |
Net Income | -5.7M | ↓ 4.34% |
Net Profit Margin | -2.7K% | ↓ 1676.17% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 447.0K | ↑ 109.86% |
Net Income | -4.8M | ↓ 15.32% |
Net Profit Margin | -1.1K% | ↑ 1599.34% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 466.0K | ↑ 4.25% |
Net Income | -6.3M | ↑ 31.18% |
Net Profit Margin | -1.4K% | ↓ 279.49% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 69.7M | ↑ 354.99% |
Total Liabilities | 5.8M | ↓ 91.51% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 61.3M | ↓ 12.03% |
Total Liabilities | 8.8M | ↑ 53.06% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 59.2M | ↓ 3.49% |
Total Liabilities | 8.3M | ↓ 5.93% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 69.2M | ↑ 16.95% |
Total Liabilities | 13.6M | ↑ 63.56% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 46.6M | ↓ 32.61% |
Total Liabilities | 4.4M | ↓ 67.52% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 45.3M | ↓ 2.88% |
Total Liabilities | 6.6M | ↑ 50.46% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 46.6M | ↓ 9.09% |
Total Liabilities | 4.4M | ↑ 15.76% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 49.0M | ↑ 5.18% |
Total Liabilities | 5.0M | ↑ 12.82% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 55.1M | ↑ 12.36% |
Total Liabilities | 6.8M | ↑ 36.66% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 49.9M | ↓ 9.51% |
Total Liabilities | 6.7M | ↓ 1.04% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 45.3M | ↓ 9.18% |
Total Liabilities | 6.6M | ↓ 1.38% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 39.9M | ↓ 11.87% |
Total Liabilities | 7.3M | ↑ 9.29% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -23.5M | ↓ 2.58% |
Investing Cash Flow | -54.7M | ↑ 821.78% |
Financing Cash Flow | 78.8M | ↑ 181.5% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -22.5M | ↓ 4.12% |
Investing Cash Flow | 16.0M | ↓ 129.28% |
Financing Cash Flow | 10.6M | ↓ 86.53% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -25.2M | ↑ 12.18% |
Investing Cash Flow | -2.7M | ↓ 116.81% |
Financing Cash Flow | 26.5M | ↑ 149.29% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -7.7M | ↓ 69.53% |
Investing Cash Flow | 19.9M | ↓ 837.64% |
Financing Cash Flow | 837.0K | ↓ 96.84% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -9.5M | ↑ 23.31% |
Investing Cash Flow | 1.7M | ↓ 91.45% |
Financing Cash Flow | 15.0K | ↓ 98.21% |
Q2 FY19 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -4.5M | ↑ 59.1% |
Investing Cash Flow | 21.9M | ↓ 140.07% |
Financing Cash Flow | -78.8M | ↑ 55.1% |
Q4 FY19 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -9.7M | ↑ 113.06% |
Investing Cash Flow | 16.0M | ↓ 26.95% |
Financing Cash Flow | 10.6M | ↓ 113.46% |
Sell
Neutral
Buy
Sol-gel Technologies Ltd is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Sol-gel Technologies Ltd | -51.08% | -62.51% | -87.47% | -96.28% | -95.58% |
![]() Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
![]() Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
![]() Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
![]() Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Sol-gel Technologies Ltd | 18.42 | NA | NA | -0.83 | -0.6 | -0.35 | NA | 1.17 |
![]() Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
![]() Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
![]() Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
![]() Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Sol-gel Technologies Ltd | Buy | $18.7M | -95.58% | 18.42 | 0.0% |
![]() Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
![]() Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on Sol-gel Technologies Ltd
Revenue is up for the last 3 quarters, 213.0K → 466.0K (in $), with an average increase of 28.2% per quarter
Netprofit is down for the last 2 quarters, -4.83M → -6.34M (in $), with an average decrease of 31.2% per quarter
In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 149.1%
In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 282.8%
Phoenix Holdings Ltd
Armistice Capital, LLC
Migdal Insurance & Financial Holdings Ltd
Harel Insurance Invests & Fin Srvcs Ltd
Kingdon Capital Management LLC
Yelin Lapidot Holdings Management Ltd
sol-gel is a clinical-stage specialty pharmaceutical company focused on developing and commercializing topical dermatological drug products. our lead product candidates, vered for the treatment of papulopustular rosacea and twin and sirs-t for the treatment of acne vulgaris (“acne”) are based upon our proprietary microencapsulation delivery system. this technology consists of microcapsules made of silica. based on our pre-clinical and clinical data, this delivery system should enable us to develop and commercialize dermatological drug products that are more effective and/or have fewer side effects than currently marketed drugs. our silica-based delivery system improves the tolerability of topical dermatological drug products by entrapping drug substances in porous silica microcapsules. this creates a protective barrier between the drug substance and the skin and controls the release rate of the drug substance. our delivery system also enables to produce novel fixed-dose combinations th
Organization | Sol-gel Technologies Ltd |
Employees | 36 |
CEO | Dr. Alon Seri-Levy |
Industry | Health Technology |
A Spac I Acquisition Corp
$0.50
+11.36%
Keyarch Acquisition Corp
$0.50
+11.36%
Connexa Sports Technologies Inc
$0.50
+11.36%
Us Value Etf
$0.50
+11.36%
First Wave Biopharma Inc
$0.50
+11.36%
Global X Msci Next Emerging
$0.50
+11.36%
Fat Projects Acquisition Corp
$0.50
+11.36%
Capital Link Global Fintech
$0.50
+11.36%
Applied Uv Inc
$0.50
+11.36%